Drug Profile
Fuzuloparib - Jiangsu HengRui Medicine
Alternative Names: Fluzoparib; HS-10160; SHR 3162Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Chinese PLA General Hospital; Jiangsu Hengrui Medicine Co.; Tianjin Medical University Cancer Institute and Hospital
- Class 2 ring heterocyclic compounds; Antineoplastics; Fluorobenzenes; Phthalazines; Pyrazines; Small molecules; Triazoles
- Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase III HER2 negative breast cancer; Pancreatic cancer; Prostate cancer
- Phase II Glioblastoma
- Phase I/II Small cell lung cancer
- No development reported Gastric cancer; Solid tumours; Triple negative breast cancer
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Adjuvant therapy) in China (PO)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Neoadjuvant therapy) in China (PO)
- 05 Dec 2023 Jiangsu HengRui Medicine completes a phase I trial for renal impairment in China (PO) (NCT05032235)